AgeX Therapeutics Cash from Financing (TTM) Analysis

AgeX Therapeutics Inc (DELISTED) (AGE:DL)

11.10 -1.50 (-11.90%) USD | NYAM | Mar 26, 16:00

12.18 +1.08 (+9.73%) After-Hours: 20:00

Cash from Financing (TTM) Chart

Historical Cash from Financing (TTM) Data

View and export this data back to 2018. Upgrade now.

Date	Value
September 30, 2023	17.00M
June 30, 2023	16.00M
March 31, 2023	16.00M
December 31, 2022	6.00M
September 30, 2022	6.00M
June 30, 2022	7.00M
March 31, 2022	6.50M
December 31, 2021	7.246M
September 30, 2021	6.738M
June 30, 2021	6.715M

Date	Value
March 31, 2021	8.022M
December 31, 2020	5.961M
September 30, 2020	6.256M
June 30, 2020	4.766M
March 31, 2020	1.95M
December 31, 2019	6.265M
September 30, 2019	4.978M
June 30, 2019	4.754M
March 31, 2019	9.763M
December 31, 2018	6.00M

Cash From Financing Definition

Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.

Read full definition.

Cash from Financing (TTM) Range, Past 5 Years

1.95M

Minimum

Mar 2020

17.00M

Maximum

Sep 2023

7.675M

Average

6.382M

Median

Cash from Financing (TTM) Benchmarks